Bausch Health Companies (BHC) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Bausch Health Companies (BHC) over the past year, gaining 41.2% versus a loss of 3.8%. Over five years, PHVS leads with a +100.5% price change compared with -78.4% for BHC. Bausch Health Companies is the larger company by market cap ($2.30 billion vs $2.22 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | PHVS |
|---|---|---|
| Share price | $6.15 | $31.68 |
| Market cap | $2.30B | $2.22B |
| 1-day change | +2.16% | +1.80% |
| YTD return | -11.51% | +14.16% |
| 1-year return | -3.76% | +41.18% |
| 5-year return | -78.41% | +100.51% |
| Forward P/E | 1.47 | — |
| EPS (TTM) | $-3.01 | $-3.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.00 | $43.25 |
| 52-week low | $4.33 | $20.65 |
| Distance from 52-week high | -23.12% | -26.75% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +21.95% | +80.62% |
| Average volume | 3.26M | 740.93K |
| Shares outstanding | 373.99M | 70.20M |
| Employees | 20,300 | 148 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed BHC by 44.9 percentage points over the past year.
- The two companies sit in different sectors: Bausch Health Companies in Healthcare and Pharvaris N.V. in Health Care.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Healthcare · Drug Manufacturers - Specialty & Generic · 20,300 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
BHC vs PHVS FAQ
Which is bigger, Bausch Health Companies or Pharvaris N.V.?
Bausch Health Companies (BHC) is larger, with a market capitalization of $2.30B compared with $2.22B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, BHC or PHVS?
PHVS returned +41.18% over the past 12 months, compared with -3.76% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Pharvaris N.V. in the same industry?
No. Bausch Health Companies is in the Healthcare sector, while Pharvaris N.V. is in Health Care.